Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation



Status:Completed
Conditions:Lymphoma
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:12/14/2017
Start Date:June 2014
End Date:December 2016

Use our guide to learn which trials are right for you!

Phase I/II Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Presence of the MyD88 L265P Mutation

Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in
approximately 30% of the patients with the activated B-cell (ABC) type of Diffuse Large B
Cell Lymphoma (DLBCL). MYD88 is an initial adapter linker protein in the signaling pathway of
the Toll Like Receptors (TLRs), including the endosomal TLRs 7, 8, and 9, for which the
ligands are nucleic acids. IMO-8400 is an oligonucleotide specifically designed to inhibit
ligand activation of TLRs 7,8, and 9. Recent studies indicate that in the presence of L265P
mutation ligand activation of those TLRs results in markedly increased signaling with
subsequent increased cell activation, cell survival, and cell proliferation. The scientific
rationale for assessing the use of IMO-8400 to treat patients with DLBCL and the L265P
mutation is based on laboratory observations that IMO-8400 inhibits ligand-based activation
of cells with the mutation and decreases the survival and proliferation of the cell
populations responsible for the propagation of the disease.

Eligible subjects will be enrolled and assigned to one of five dose cohorts. Treatment will
be administered by subcutaneous injection until progression or intolerable toxicity.

Inclusion Criteria:

- Patients must have a diagnosis of Diffuse Large B Cell Lymphoma (DLBCL) of non-GCB
subtype, established according to the World Health Organization (WHO) criteria that
has been tested for the MyD88 L265P mutation.

- In addition to the above, key inclusion and exclusion criteria are listed below.

1. Be at least 18 years of age

2. Agree to use contraception

Exclusion Criteria:

1. Is nursing or pregnant

2. DLBCL of GCB subtype

3. Has BMI > 34.9 kg/m2

4. Has a positive test for human immunodeficiency virus (HIV-1 or -2) hepatitis C virus
(HCV) or hepatitis B surface antigen (HBsAg)

5. Receiving chronic systemic corticosteroid therapy > 20 mg of prednisone daily

6. Being treated with other anti-cancer therapies (approved or investigational)

7. Has an active infection requiring systemic antibiotics

8. Has had surgery requiring general anesthesia within 4 weeks of starting the study

9. Has heart failure of Class III or IV
We found this trial at
12
sites
630 W 168th St
New York, New York
212-305-2862
Principal Investigator: Ahmed Sawas, MD
Columbia University Medical Center Situated on a 20-acre campus in Northern Manhattan and accounting for...
?
mi
from
New York, NY
Click here to add this to my saved trials
201 Dowman Dr
Atlanta, Georgia 30303
(404) 727-6123
Principal Investigator: Leonard Heffner, MD
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
9500 Euclid Avenue
Cleveland, Ohio 44106
216.444.2200
Principal Investigator: Brian Hill, MD
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2220 Pierce Ave
Nashville, Tennessee 37232
615-936-8422
Principal Investigator: Nishita Reddy, MD
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
?
mi
from
Nashville, TN
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Ann LaCasce, M.D.
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Decatur, Illinois 62526
Principal Investigator: James Wade, MD
?
mi
from
Decatur, IL
Click here to add this to my saved trials
757 Westwood Plaza
El Pueblo De Nuestra Señora De Los Ángeles De Porciúncula, California 90095
?
mi
from
El Pueblo De Nuestra Señora De Los Ángeles De Porciúncula, CA
Click here to add this to my saved trials
30 Prospect Ave
Hackensack, New Jersey 07601
(201) 996-2000
Principal Investigator: Tatyana Feldman, MD
Hackensack University Medical Center Hackensack University Medical Center, part of the Hackensack University Health Network,...
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Yashuhiro Oki, M.D.
?
mi
from
Houston, TX
Click here to add this to my saved trials
Lafayette, Indiana 47905
Principal Investigator: Wael Harb, MD
?
mi
from
Lafayette, IN
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Grzegorz Nowakowski, M.D.
?
mi
from
Rochester, MN
Click here to add this to my saved trials
660 South Euclid Avenue
San Luis, Missouri 63110
?
mi
from
San Luis, MO
Click here to add this to my saved trials